Panacea Biotec has posted impressive performance during the year ended March 2011 and its consolidated net sales reached at Rs.1,143 crore from Rs.900 crore in the previous year, representing a smart gain of 27 per cent. Its consolidated net profit also moved up by 83 per cent to Rs.132.48 crore from Rs.72.40 crore. The company recommended equity dividend of 75 per cent (Re 0.75 per share of Re 1) for the year ended March 2011.


Its EBDITA went up by 78.3 per cent to Rs.276.75 crore from Rs.155.25 crore. During the year 2009-10, the company incurred a foreign exchange loss of Rs.63.53 crore as against a gain of Rs.0.58 crore in the 2010-11. The company's vaccines sales increased by 27.2 per cent to Rs.850.83 crore from Rs.668.74 crore and that of formulations improved by 24.4 per cent to Rs.300.73 crore from Rs.241.73 crore.


As against the equity capital of Rs.6.13 crore, Panacea's reserves and surplus amounted to Rs.642.74 crore as compared to Rs.694.05 crore in the previous year, a degrowth of 7.4 per cent. Its borrowings increased by 22.6 per cent to Rs.865.18 crore from Rs.705.44 crore.


The company launched three new products viz., PacliALL, Exeroz-F and Evergraf during the last quarter ended March 2011. It entered into an agreement with Laboratorios Clausen, Uruguay for grant of non-exclusive marketing rights of he company's medicine “Tacrolimus (Pangraph) for few markets in Europe. During the fourth quarter, it redeemed the balance outstanding Tranche 2 FCCBs with nominal value of US$ 36.8 million.